Trevi Therapeutics, Inc.
10:45 AM - 11:00 AM (EST), Tuesday, February 7, 2023 ・ Music Box
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis. Trevi has successfully completed a Phase 2 trial of Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and reported a statistically significant result for cough reduction (p<0.0001). Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases.
Ticker:
TRVI
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Respiratory
Lead Product in Development:
Haduvio™ (nalbuphine ER)
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
